2018 marked the 10 year anniversary since the Journal of Hematology & Oncology published its first article. Over the past decade, the journal has established itself in the top quartile of journals in both its fields worldwide.
To mark this occasion, we're looking back at the journal's milestone achievements and highlighting some of the best content from the past 10 years.
"It is a real honor for me to congratulate the Journal of Hematology and Oncology (JHO) for its 10th anniversary. JHO has proven itself during these years as a leading journal in the field of hematology, including stem cell transplantation and cellular therapy, with numerous original articles— many of them practice changers. And I may guess it is only the beginning. Happy anniversary!"
– Prof Arnon Nagler, JHO author
Tel Aviv University, Israel
"Over just 10 years, JHO has become one of the journals in the field of hematology/oncology with an impact factor of >6 under the leadership of Prof. Delong Liu. It was a wonderful experience to publish my clinical trial results at JHO. I am confident that JHO will continue to publish high quality papers to make a strong impact in the hematology/oncology fields."
– Dr Hongtao Liu, CAHON member
University of Chicago Medical Center, USA
The effects of β-glucan on human immune and cancer cells
Chan et al.
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan et al.
Mechanism of action of lenalidomide in hematological malignancies
Kotla et al.
Clinical applications of mesenchymal stem cells
Wang et al.
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers
Li et al.
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
Molderings et al.
The effects of β-glucan on human immune and cancer cells
Chan et al.
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers
Li et al.
Ibrutinib and novel BTK inhibitors in clinical development
Akinleye et al.
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Shi et al.
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
Molderings et al.
Checkpoint inhibitors in hematological malignancies
Ok & Young
Bispecific antibodies and their applications
Fan et al.
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Wu et al.
Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test
Hsueh et al.
Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Citation Impact 2023
Journal Impact Factor: 29.5
5-year Journal Impact Factor: 26.9
Source Normalized Impact per Paper (SNIP): 4.489
SCImago Journal Rank (SJR): 7.522
Speed 2023
Submission to first editorial decision (median days): 4
Submission to acceptance (median days): 59
Usage 2023
Downloads: 3,173,795
Altmetric mentions: 2,671
06 April 2023
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).
Comments from our community
"Journal of Hematology & Oncology has quickly emerged as one of the significant journals in its fields. With its high editorial standards, its value to the scientific community and Prof. Delong Liu at the helm, I have no doubt that the journal will continue to go from strength to strength in the years to come."
– Dr Srdan Verstovsek, JHO Editorial Board member
MD Anderson Cancer Center, USA